Dermatology candidate KB111 for Hailey-Hailey disease has begun enrolling patients in an open-label study, with interim results also targeted before year-end. Research and development costs were $14.5 million, while selling, general and administrative expenses rose to $39.9 million, reflecting commercial expansion. For the first six months of 2026, product revenue totaled $235.6 million and net income reached $110.7 million. Krystal Biotech has built its platform around a proprietary herpes simplex virus type 1 vector that enables redosable gene delivery. Upcoming milestones include the fourth-quarter data from the KB803 study, enrollment completion and later readouts from KB801, interim updates across respiratory and dermatology programs, and further international launches of VYJUVEK.